Productivity losses in chronic obstructive pulmonary disease: A population-based survey

BMJ Open Respiratory Research

Volumn 1, Issue 1, 2014, Pages

  Erdal, Marta ^a   Johannessen, Ane ^a   Askildsen, Jan Erik ^b   Eagan, Tomas ^a,b   Gulsvik, Amund ^b   Grønseth, Rune ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENTEEISM; ANTHROPOMETRY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DEMOGRAPHY; DISEASE SEVERITY; ECONOMIC EVALUATION; FEMALE; HEALTH CARE SURVEY; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MALE; MULTIVARIATE ANALYSIS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SPIROMETRY; TELEPHONE INTERVIEW; WORK DISABILITY;

EID: 85006683136     PISSN: None     EISSN: 20524439     Source Type: Journal    
DOI: 10.1136/bmjresp-2014-000049     Document Type: Article

References (29)

1. The World Health Organization (WHO). Projections of mortality and causes of death, 2015 and 2030. http://www.who.int/healthinfo/global_burden_disease/projections/en/ (accessed 26 Feb 2014).
2. Miller JD, Foster T, Boulanger L, et al. Direct costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) data. COPD 2005;2:311–18.
3. Nielsen R, Johannessen A, Benediktsdottir B, et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study. Eur Respir J 2009;34:850–7.
4. Jansson SA, Backman H, Stenling A, et al. Health economic costs of COPD in Sweden by disease severity—has it changed during a ten years period? Respir Med 2013;107:1931–8.
5. Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics 1992;2:1–4.
6. Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1997.
7. Allen H, Rogers W, Bunn WB III. Managing the burden of chronic obstructive pulmonary disease on workforce health and productivity: upping a leading employer’s game. J Occup Environ Med 2012;54:1064–77.
8. Darkow T, Kadlubek PJ, Shah H, et al. A retrospective analysis of disability and its related costs among employees with chronic obstructive pulmonary disease. J Occup Environ Med 2007;49:22–30.
9. Lou P, Zhu Y, Chen P, et al. Vulnerability, beliefs, treatments and economic burden of chronic obstructive pulmonary disease in rural areas in China: a cross-sectional study. BMC Public Health 2012;12:287.
10. Montes de Oca M, Halbert RJ, Talamo C, et al. Paid employment in subjects with and without chronic obstructive pulmonary disease in five Latin American cities: the PLATINO study. Int J Tuberc Lung Dis 2011;15:1259–64, i–iii.
11. Nishimura S, Zaher C. Cost impact of COPD in Japan: opportunities and challenges? Respirology 2004;9:466–73.
12. Tinkelman D, Nordyke RJ, Isonaka S, et al. The impact of chronic obstructive pulmonary disease on long-term disability costs. J Manag Care Pharm 2005;11:25–32.
13. Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003;97(Suppl C):S3–14.
14. Nielsen R, Klemmetsby M, Gulsvik A. Economics of COPD: literature review and experiences from field work. Clin Respir J 2008;2(Suppl 1):104–10.
15. Nielsen R, Johannessen A, Omenaas ER, et al. Excessive costs of COPD in ever-smokers. A longitudinal community study. Respir Med 2011;105:485–93.
16. Sorheim IC, Johannessen A, Grydeland TB, et al. Case-control studies on risk factors for chronic obstructive pulmonary disease: how does the sampling of the cases and controls affect the results? Clin Respir J 2010;4:89–96.
17. Gulsvik A, Tosteson T, Bakke P, et al. Expiratory and inspiratory forced vital capacity and one-second forced volume in asymptomatic never-smokers in Norway. Clin Physiol 2001;21:648–60.
18. ATS. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995;152: 1107–36.
19. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196–204.
20. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.
21. Jansson SA, Andersson F, Borg S, et al. Costs of COPD in Sweden according to disease severity. Chest 2002;122:1994–2002.
22. Marrie RA, Dawson NV, Garland A. Quantile regression and restricted cubic splines are useful for exploring relationships between continuous variables. J Clin Epidemiol 2009;62:511–17.e1.
23. Lindberg A, Bjerg A, Ronmark E, et al. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking report from the obstructive lung disease in Northern Sweden studies. Respir Med 2006;100:264–72.
24. Waatevik M, Skorge TD, Omenaas E, et al. Increased prevalence of chronic obstructive pulmonary disease in a general population. Respir Med 2013;107:1037–45.
25. Jansson SA, Lindberg A, Ericsson A, et al. Cost differences for COPD with and without physician-diagnosis. COPD 2005;2:427–34.
26. Evans C, Crawford B. Patient self-reports in pharmacoeconomic studies. Their use and impact on study validity. Pharmacoeconomics 1999;15:241–56.
27. Nielsen R. Costs of chronic obstructive pulmonary disease in a general population. Methodological aspects and longitudinal perspectives [dissertation]. Bergen: University of Bergen, 2011.
28. Statistics Norway. Labour force survey, seasonally-adjusted monthly figures. https://www.ssb.no/en/arbeid-og-lonn/statistikker/akumnd (accessed 26 Feb 2014).
29. Rutten-van Molken MP, Goossens LM. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics 2012;30:271–302.